Prelude Therapeutics Incorporated
News
(2)April 2026
Prelude (PRLD) announces major capital raise selling shares and warrants
# 📜 What This Document Is ✨ This document is an 8-K filing, which is a very important, mandatory filing used to announce major, unexpected events that happen *after* the company has already been publicly listed. Think of it like an urgent "Heads Up!" bulletin to investors. In simple terms, Prelud
PRLD shows promising preclinical data; aims for 2026 IND filing
# 📑 What This Document Is 📄 This filing is a material disclosure (an 8-K) announcing significant scientific progress for Prelude Therapeutics. It serves to update investors and the public on the impressive preclinical data generated for the company's lead drug candidate, PRT13722. 👉 Essentially,
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.